Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
NCT03971422Phase 3Completed
- Sponsor
- UCB
- Start
- Jun 2019
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of rozanolixizumab in myasthenia gravis (MG) (3 arms), sponsored by UCB. Primary endpoint: Myasthenia Gravis-Activities of Daily Living Score at Day 43. Started Jun 2019; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT03971422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971422.